Guidance: Individualized Human Genome Editing Products, Considerations for BLA Submission and Postapproval Management

Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry; Availability

DATES:

Submit either electronic or written comments on the draft guidance by November 27, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

Electronic Submissions

Submit electronic comments in the following way:

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.

• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

• Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA-2026-D-11783 for "Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management." Received comments will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

• Confidential Submissions-To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the draft guidance to the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3103, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist the office in processing your requests. The draft guidance may also be obtained by mail by calling CBER at 1-800-835-4709 or 240-402-8010. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft document titled "Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management." The draft guidance document, intended for sponsors and applicants developing individualized GE products, provides recommendations for how an individualized GE product that includes multiple product variants can be submitted in a single BLA under section 351(a) of the Public Health Service Act (PHS Act) (42 U.S.C. 262(a)). When finalized, this guidance will describe FDA's current thinking regarding how to specify the extent of GE component variation in a BLA and how to add new product variants to the BLA after licensure. This guidance also addresses related topics, including potency and safety evaluation of product variants, manufacturing process validation, labeling and indication statements, and drug naming and identification. This guidance is intended to complement existing FDA guidances on GE products addressing investigational new drug (IND)-stage chemistry, manufacturing, and controls (CMC); nonclinical and clinical trial design; evidentiary standards for approval of individualized therapies; and leveraging of CMC, nonclinical, and clinical knowledge across GE programs  ^(1 2 3) with additional advice and considerations on how to prepare and submit BLAs and BLA supplements for individualized GE products.

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on "Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management." It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

As we develop final guidance on this topic, FDA will consider comments on costs or cost savings the guidance may generate, relevant for Executive Order 14192.

II. Paperwork Reduction Act of 1995

While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information in 21 CFR parts 210 and 211 pertaining to manufacturing, processing, packing, and holding of finished pharmaceuticals and biological products for human use (CGMP regulations) have been approved under OMB control number 0910-0139. The collections of information in 21 CFR 312.23(a)(7)(i) pertaining to submission of proper identification, quality, purity, and strength of an investigational drug in an IND application have been approved under OMB control number 0910-0014. The collections of information in 21 CFR 600.14(b) pertaining to biological product deviation reporting is included in OMB control number 0910-0458. The collections of information in 21 CFR part 601 pertaining to biological license applications have been approved under OMB control number 0910-0338.

III. Electronic Access

Persons with access to the internet may obtain the draft guidance at https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.

⁽¹⁾  See Guidance for Industry "Human Gene Therapy Products Incorporating Human Genome Editing," January 2024, https://www.fda.gov/media/156894/download.

⁽²⁾  See Draft Guidance for Industry "Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause," February 2026, https://www.fda.gov/media/191247/download. When finalized, this guidance will represent FDA's current thinking on this topic.

⁽³⁾  See Draft Guidance for Industry "Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing," June 2026, https://www.fda.gov/media/192810/download. When finalized, this guidance will represent FDA's current thinking on this topic.